Navigation Links
Vicus Therapeutics Announces Initiation of Phase 2 Trial to Evaluate VT-122 in Patients with Liver Cancer Receiving Nexavar
Date:12/27/2010

ue, weakness, pain, dyspnea, nausea, malaise, anxiety, depression and poor performance status.(1,2)  This symptom cluster is  further associated with poor tolerance, adherence and response to anti-cancer therapy, disease progression and reduced life expectancy.(1,2)

About Hepatocellular Carcinoma

Hepatocellular carcinoma is the most common form of liver cancer and is responsible for about 90 percent of the primary malignant liver tumors in adults.  Liver cancer is the sixth most common cancer in the world and the third leading cause of cancer-related deaths globally.  

About VT-122

VT-122 is a novel investigational combination of etodolac and propranolol that targets pathways associated with cancer-induced systemic inflammation, a suspected cause of cancer cachexia.(1,2) VT-122 has demonstrated the ability to increase lean body mass (muscle) and lower other markers of systemic inflammation in a Phase 2 trial of patients with advanced lung cancer.(3) Preclinical and clinical studies show that propranolol and etodolac, when used individually, attenuate systemic inflammation, hypermetabolism, and weight loss.(4,5,6)  Furthermore, non-clinical studies show that this combination acts synergistically to attenuate systemic inflammation, activate cellular immunity, reduce metastasis, and increase animal survival.(7)

About Nexavar

Nexavar is approved in the U.S. for the treatment of patients with unresectable liver cancer and for the treatment of patients with advanced kidney cancer.  Nexavar inhibits both the tumor cell and tumor vasculature.  In preclinical studies, Nexavar has been shown to inhibit members of two classes of kinases thought to be involved in both cell proliferation (growth) and angiogenesis (blood supply) – two impo
'/>"/>

SOURCE Vicus Therapeutics, LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Vicus Therapeutics Records Last Patient Visit of Phase 2, VT-122 Trial for the Treatment of Cachexia in Patients With Advanced Lung Cancer
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. King Pharmaceuticals and Pain Therapeutics Announce Resubmission of New Drug Application for REMOXY®
4. PTC Therapeutics Completes Enrollment of Phase 3 Trial of Ataluren in Patients with Cystic Fibrosis
5. Silence Therapeutics Provides Year-end Update
6. Angelica Therapeutics Receives a $244,479 Qualified Therapeutic Discovery Project Grant for Its Anti-Cancer Drug
7. Talecris Biotherapeutics Enrolls Patients in Clinical Trial Evaluating Two Doses of PROLASTIN®-C
8. Osseon® Therapeutics Names Gary Coughlen, CPA as New Chief Financial Officer
9. Amicus Therapeutics Awarded $500,000 Grant from The Michael J. Fox Foundation for Development of Next-Generation Pharmacological Chaperone to Treat Parkinsons Disease
10. Orexigen® Therapeutics Investigational Drug Contrave® Receives Positive Recommendation from FDA Advisory Committee for Treatment of Obesity
11. Nile Therapeutics Receives NASDAQ Notice; Will Request Hearing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014  Medical Science Liaisons play a large role ... the medical device industry and key stakeholders, the role ... years as the device industry relies on them to ... by benchmarking firm, Best Practices, LLC, one area where ... is by harnessing new technology to enable education. Online ...
(Date:12/22/2014)... 22, 2014 NxStage Medical, Inc. (NASDAQ: ... dialysis products, announced today that the U.S. Food ... One™ to perform hemodialysis overnight while the patient ... hemodialysis. NxStage,s® System One is the first and ... this indication. Home nocturnal hemodialysis ...
(Date:12/22/2014)... , Dec. 22, 2014 Research and Markets ... the "US Self-monitoring Blood Glucose Market" report ... This market insight focuses on the ... the United States . Reimbursement analysis and ... product analyses for more than 73 SMBG meters have ...
Breaking Medicine Technology:Role of Medical Science Liaisons Evolving in Medical Device Sector 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3US Self-monitoring Blood Glucose Market 2
(Date:12/24/2014)... 2014 “ Relax Melodies ” was ... which features the latest and coolest mobile applications on ... mobile technology expert and host of NewsWatch, conducted the ... soothes users so they can fall asleep. , According ... say they have some sort of difficulty sleeping. Since ...
(Date:12/24/2014)... In June 2014, 15 injured veterans ... hand cycles and recumbent bicycles nearly 800 miles from ... CanAm Veterans’ Challenge . “Capital to Capital,” the new ... this inspiring ride, is now available through multiple online ... photographs taken during the two-week ride, the 92 page ...
(Date:12/24/2014)... fear of terrorists may damage your heart and increase your ... suggests. , , Conducted by researchers from the Hebrew University ... threat of war and terrorism has been a part of ... test whether fear of terrorism can predict an increase in ... Soreq, a professor of molecular neuroscience, said in a university ...
(Date:12/22/2014)... As part of a company-wide commitment ... San Diego and surrounding areas, Golden Care ... team with ongoing online training courses. , Online ... by Caregiverlist®. Caregiverlist® is “the premiere service ... reliable eldercare options, highest quality ratings and outstanding ...
(Date:12/22/2014)... 2014 The founders of United ... online certification provider, are proud to announce the launch ... site now features a more user-friendly layout, including a ... , As a company spokesperson for United ... into a single page during the checkout process, and ...
Breaking Medicine News(10 mins):Health News:An Application to Help with Insomnia was Featured on NewsWatch Television on December 19, 2014 2Health News:New Commemorative Book Celebrates CanAm Veterans’ Challenge Bike Ride 2Health News:New Commemorative Book Celebrates CanAm Veterans’ Challenge Bike Ride 3Health News:Terrorism Fears May Shorten Your Life, Study Finds 2Health News:Golden Care Partners with Nationally Recognized Caregiver Training Service 2Health News:ACLS Online Certification Website ACLS-PALS-BLS.com Now Features a New and User-Friendly Layout 2
... April 4, 2008 Companies align,commercial and portfolio ... an annual sales volume of $10 to 20 ... the early-stage commercialization team along,with approximately eight portfolio ... is approximately four to three, commercial to,portfolio management ...
... Lilly and Company,(NYSE: LLY ) today announced ... for FORSTEO(R) (teriparatide [rDNA origin] injection) for the,treatment ... women and men at increased risk for fracture.,This ... February by,the Committee for Medicinal Products for Human ...
... 3, 2008 To promote,the U.S. Department ... for a,Healthy Future" initiative, Acting U.S. Surgeon ... visited with several community leaders at A.I.,DuPont ... in reducing,childhood obesity in Delaware., (Photo: ...
... Targeted mass,media campaigns alone can be effective ... to adopt safer,sex practices, according to a ... the University of Kentucky with funding from ... public health campaigns, particularly those promoting healthy,behaviors, ...
... Security determined outcome of ,terrible 2s, battles but not ... News) -- The way mothers and their 2-year-olds relate ... the frequency -- of conflict during the "terrible twos." ... quality and frequency of such conflicts, according to a ...
... Plus, meet and greet fitness and figure professionals, PITTSBURGH, April 3, 2008 , ... Frahn WHAT: The MORE ... of the More Magazine Marathon and Half-Marathon) WHEN: 12 -7 p.m. April ... 135 W. 18th Street, New York (between 6th and 7th ...
Cached Medicine News:Health News:Early-stage Commercialization Success: Pharma Companies Adjust Resources in Light of Industry Changes 2Health News:FORSTEO(R) Receives Approval from the European Commission for the Treatment of Glucocorticoid-Induced Osteoporosis 2Health News:FORSTEO(R) Receives Approval from the European Commission for the Treatment of Glucocorticoid-Induced Osteoporosis 3Health News:FORSTEO(R) Receives Approval from the European Commission for the Treatment of Glucocorticoid-Induced Osteoporosis 4Health News:FORSTEO(R) Receives Approval from the European Commission for the Treatment of Glucocorticoid-Induced Osteoporosis 5Health News:Delaware's Campaign to Make Kids Healthy Gets Boost from US Top Doc 2Health News:Delaware's Campaign to Make Kids Healthy Gets Boost from US Top Doc 3Health News:Study Finds Mass Media Campaigns Alone Can Effectively Reduce High-Risk Sexual Behavior Among Impulsive, Sensation-Seeking Young Adults 2Health News:Study Finds Mass Media Campaigns Alone Can Effectively Reduce High-Risk Sexual Behavior Among Impulsive, Sensation-Seeking Young Adults 3Health News:Mother-Child Bond Affects Quality of Conflict Resolution 2Health News:GNC to Run Sweepstakes, Raffle Fitness Equipment at MORE Magazine Health and Wellness Expo 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: